Raybow to expand US sites

Raybow USA, the North American subsidiary of Chinese pharmaceutical CDMO Raybow Pharmaceuticals, is panning to invest $15.8 million to expand its site at Brevard, North Carolina, over the coming five years. This will triple capacity and add 74 jobs to the existing 24, including research chemists, pilot-plant personnel and supervisors.

The site focuses on early-stage R&D and process research through Phase II clinical trials, with services such as custom synthesis, process development and optimisation and analytical services. It was originally founded by Peter Newsome and Roger Frisbee in 1999 as PharmAgra Labs and was acquired by Raybow, itself a subsidiary of Zhejiang Jiuzhou Pharmaceutical, in November 2019. T

aizhou-based Raybow itself dates back to 2008 and employs over 1,500. It has two manufacturing sites and two process R&D hubs in China itself, as well as this operation and also sales and marketing offices in Los Angeles, Princeton, New Jersey, and Copenhagen, Denmark. It is active throughout the pharmaceutical development chain, including making niche commercial APIs.